All Articles
Browse the full archive, newest first.
Strategic view: Japan rallies past Australia, clinches WBC group
Strategic implications in focus: Defending champion Japan rallied from 1-0 down to beat Australia 4-3 in the World Baseball Classic on Sunday behind a two-run homer from Masataka Yoshida with two outs in the seventh inning.
Editorial Staff Mar 8
Primary Care Physician Burnout: A Decade of Declining Satisfaction
A comprehensive analysis reveals troubling trends in primary care physician satisfaction in the US and nine comparator nations, indicating systemic issues that could affect healthcare outcomes.
Editorial Staff Mar 8
Strategic view: MLB Free Agent Tracker: Top 50 FAs Signings for 2026 Season
Strategic implications in focus: Here are the latest signings from baseball's hot stove as spring training camps continue.
Editorial Staff Mar 8
Strategic view: Serbia: Fears rise over the last independent media outlets
Strategic implications in focus: Concerns grow over potential shifts in media independence following a deal with a state-owned telecommunications company.
Editorial Staff Mar 8
Ibrox Incident Signals Underlying Tensions in Scottish Football Rivalry
The pitch invasion at Ibrox after Celtic's win reveals deeper issues within fan engagement and security in Scottish football.
Editorial Staff Mar 8
Strategic view: Jim Cramer on Howmet Aerospace: “It’s Just in The Sweet Spot”
Strategic implications in focus: Jim Cramer discusses the promising outlook for Howmet Aerospace.
Editorial Staff Mar 8
Strategic view: Jim Cramer on AeroVironment, Inc.: “It’s a Long-time Cramer Fave, But Things Don’t Seem Right Here”
Strategic implications in focus: Jim Cramer expresses concerns about AeroVironment, Inc., despite its long-standing popularity.
Editorial Staff Mar 8
Strategic view: 5 Lessons from Vinay Prasad’s Turbulent Tenure at the FDA
Strategic implications in focus: Vinay Prasad's unique ability to attract criticism — even when his bosses, including the president, wanted him to keep his head low — did him in at the FDA.
Editorial Staff Mar 8